跳至主要内容
临床试验/NCT00162461
NCT00162461Unknown不适用

The Use of Phenytoin Metabolic Ratio as a Putative Marker of CYP2C9 Activity In-vivo

Hadassah Medical Organization1 个研究点 分布在 1 个国家目标入组 1,200 人开始时间: 1998年8月最近更新:
适应症
干预措施
相关药物

试验速览

阶段
不适用
入组人数
1,200
试验地点
1
主要终点
Correlation between phenytoin metabolic ratio and CYP2C9 genotype

研究概览

简要总结

The use of phenytoin metabolism to produce S-HPPH accounts for more than 85% of its metabolism. This metabolic pathway is mediated by the activity of CYP2C9.

The purpose of the present study is:

  1. To confirm the use of phenytoin metabolic ratio as a marker of CYP2C9 activity
  2. To correlate phenytoin metabolic ratio with CYP2C9 genotype
  3. To study the frequency distribution of CYP2C9 activity in-vivo

研究设计

研究类型
Interventional
分配方式
Na
干预模型
Single Group
主要目的
Other
盲法
None

入排标准

年龄范围
20 Years 至 50 Years(Adult)
性别
All
接受健康志愿者

入选标准

  • Age range of 20-50 years old
  • Absence of significant disease states

排除标准

  • The presence of significant disease states
  • The use of drugs (including birth control pills)

研究组 & 干预措施

Phenytoin

Experimental

干预措施: Phenytoin single dose (300 mg) (Drug)

结局指标

主要结局

Correlation between phenytoin metabolic ratio and CYP2C9 genotype

时间窗: 24 hours

Frequency distribution of phenytoin metabolic ratio in the population

时间窗: 24 hours

次要结局

未报告次要终点

研究者

申办方类型
Other
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验

Evaluation of CYP2C9 Activity | 临床试验